Cell Biology Goes Big Science

The Allen Institute for Cell Science launches with $100 million in philanthropic funds.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
WIKIMEDIA, PETER ZNAMENSKIYA new institute focused on cell biology is set to launch in Seattle. With $100 million in funding over five years from philanthropist Paul G. Allen, the Allen Institute for Cell Science will share a building with the Allen Institute for Brain Science—at least until September—and aims to attract up to 75 scientists in the next three years.
“The complexity of the cell presents a barrier to attempts to study it as an integrated system,” the new institute’s executive director, Alan “Rick” Horwitz, told reporters during a press briefing at the American Society for Cell Biology (ASCB) meeting in Philadelphia today (December 8). “We plan to leverage the strengths of academic research . . . to create tools and models and an integrated approach [to cell biology] that will benefit the whole community.”
“We will take big team science approaches to systematically study and integrate parts of human cells in one institute,” added Allen Institute CEO Allan Jones.
Much like its neuroscience-centric sister institute, the new cell science facility will make its research results publicly available, Jones explained, adding that its first project, the Allen Cell Observatory, will involve the creation of a human induced pluripotent stem cell library.
“To understand disease from a cellular point of view,” said Horwitz, “you have to understand the cell.”
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies